Maksim D. Efimov
Maksim D. Efimov has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Aleksey V. Bereznikov
Russian Biotechnological University (ROSBIOTECH), Moscow, Russia; AlfaStrakhovanie — OMS LLC, Moscow, Russia
7 shared publications - Sergei O. Shkitin
Russian Biotechnological University (ROSBIOTECH), Moscow, Russia; AlfaStrakhovanie — OMS LLC, Moscow, Russia
7 shared publications - Hunan L. Julhakyan
National Medical Research Center of Hematology
3 shared publications Березников А. В.
ФГБОУ ВО «Российский биотехнологический университет (РОСБИОТЕХ)»; ООО «АльфаСтрахование – ОМС
2 shared publicationsДжулакян У. Л.
ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России
2 shared publicationsУ. Л. Джулакян
ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России
2 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 4
Respiratory safety of morphine, trimeperidine, and Tafalgin for postoperative analgesia: a retrospective secondary analysis of pharmacoepidemiological and clinical and economic data
INTRODUCTION: Opioid-induced respiratory depression (OIRD) and related complications remain a key concern of postoperative analgesia, particularly in high perioperative-risk patients with obesity and type 2 diabetes mellitus (T2DM). OBJECTIVE: To compare the respiratory safety and clinico-economic outcomes of postoperative analgesia with morphine, trimeperidine, and Tafalgin in high-risk patients. MATERIALS AND METHODS: A retrospective secondary analysis of two datasets: a pharmacoepidemiological cohort of 6,000 patients (2,000 each in the Tafalgin, morphine, and trimeperidine groups) and a regional pharmacoeconomic cohort of 1,500 patients with T2DM and obesity (180, 675, and 645, respectively). Event rates were compared using Pearson's χ2 test, with Fisher's exact test for rare events, calculating relative risk (RR) and 95% CI; Tafalgin served as reference. RESULTS: Groups were comparable in baseline characteristics and surgical structure (all p > 0.05). The 6-month pneumonia rate was 1.15 % with Tafalgin vs 8.20 % with morphine (RR 7.13; 95% CI 4.63–10.98; p < 0.001) and 7.45 % with trimeperidine (RR 6.48; 95% CI 4.19–10.01; p < 0.001). In the regional cohort, complication rates were 5.56, 19.41, and 18.45 % (RR 3.49 and 3.32; p < 0.001). In class II–III obesity (BMI ≥ 35.0 kg/m2), Tafalgin's advantage increased with obesity severity: the number needed to treat (NNT) versus morphine fell from 4.2 to 3.1. Over a 12-month horizon, total direct costs per patient were lower with Tafalgin by 4,528–4,994 RUB, corresponding to a dominant strategy. CONCLUSIONS: Tafalgin use was associated with fewer respiratory complications and lower total direct costs than morphine and trimeperidine, with differences most pronounced in high-risk patients. Results should be interpreted in view of the retrospective and aggregated nature of the source data.
- 31 October 2026
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 4
Open AccessRespiratory safety of morphine, trimeperidine, and Tafalgin for postoperative analgesia: a retrospective secondary analysis of pharmacoepidemiological and clinical and economic data
INTRODUCTION: Opioid-induced respiratory depression (OIRD) and related complications remain a key concern of postoperative analgesia, particularly in high perioperative-risk patients with obesity and type 2 diabetes mellitus (T2DM). OBJECTIVE: To compare the respiratory safety and clinico-economic outcomes of postoperative analgesia with morphine, trimeperidine, and Tafalgin in high-risk patients. MATERIALS AND METHODS: A retrospective secondary analysis of two datasets: a pharmacoepidemiological cohort of 6,000 patients (2,000 each in the Tafalgin, morphine, and trimeperidine groups) and a regional pharmacoeconomic cohort of 1,500 patients with T2DM and obesity (180, 675, and 645, respectively). Event rates were compared using Pearson's χ2 test, with Fisher's exact test for rare events, calculating relative risk (RR) and 95% CI; Tafalgin served as reference. RESULTS: Groups were comparable in baseline characteristics and surgical structure (all p > 0.05). The 6-month pneumonia rate was 1.15 % with Tafalgin vs 8.20 % with morphine (RR 7.13; 95% CI 4.63–10.98; p < 0.001) and 7.45 % with trimeperidine (RR 6.48; 95% CI 4.19–10.01; p < 0.001). In the regional cohort, complication rates were 5.56, 19.41, and 18.45 % (RR 3.49 and 3.32; p < 0.001). In class II–III obesity (BMI ≥ 35.0 kg/m2), Tafalgin's advantage increased with obesity severity: the number needed to treat (NNT) versus morphine fell from 4.2 to 3.1. Over a 12-month horizon, total direct costs per patient were lower with Tafalgin by 4,528–4,994 RUB, corresponding to a dominant strategy. CONCLUSIONS: Tafalgin use was associated with fewer respiratory complications and lower total direct costs than morphine and trimeperidine, with differences most pronounced in high-risk patients. Results should be interpreted in view of the retrospective and aggregated nature of the source data.
- 20 October 2026
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 22 (2) , 113-126
Prognostic value of relative dose intensity of chemotherapy and anemia correction strategies for 12-month progression-free survival in ovarian cancer
Background. Relative dose intensity (RDI) of chemotherapy and anemia correction may be associated with treatment outcomes in ovarian cancer. Aim. To assess the associations of reduced RDI and different anemia correction strategies with 12-month progression-free survival (PFS). Materials and methods. This retrospective multicenter cohort study included 595 patients with stage IIIB–IV ovarian cancer who received care at 26 healthcare institutions. Follow-up started on the date of laboratory-confirmed anemia during first-line chemotherapy and covered a 365-day observation period. Three RDI categories and four anemia correction strategies were compared. Results. A total of 301 PFS events (50.6 %) were recorded. The proportions of patients without a recorded PFS event were 73.7 %, 51.5 %, and 19.5 % in the RDI ≥85 %, 85–65 %, and 65 % groups, respectively. These proportions were 57.8 % in patients with moderate anemia and 32.5 % in those with severe anemia; the OR for a PFS event in severe versus moderate anemia was 2.85 (95 % confidence interval (CI) 1.99–4.07). With epoetin alfa as the reference, the odds ratio for a PFS event were 6.99 (95 % CI 4.21–11.59) for no anemia correction, 5.44 (95 % CI 3.37–8.76) for iron preparations, and 7.75 (95 % CI 4.72–12.71) for blood transfusions. In the multivariable Cox model, the adjusted hazard ratio was 5.60 (95 % CI 3.99–7.86) for RDI 65 % versus ≥85 % and 5.71 (95 % CI 3.88–8.42) for no correction versus epoetin alfa. Conclusion. In this retrospective cohort, higher RDI and epoetin alfa use were associated with a greater proportion of patients without a recorded PFS event over 12 months of follow-up.
- 20 October 2026
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 22 (2) , 113-126
Prognostic value of relative dose intensity of chemotherapy and anemia correction strategies for 12-month progression-free survival in ovarian cancer
Background. Relative dose intensity (RDI) of chemotherapy and anemia correction may be associated with treatment outcomes in ovarian cancer. Aim. To assess the associations of reduced RDI and different anemia correction strategies with 12-month progression-free survival (PFS). Materials and methods. This retrospective multicenter cohort study included 595 patients with stage IIIB–IV ovarian cancer who received care at 26 healthcare institutions. Follow-up started on the date of laboratory-confirmed anemia during first-line chemotherapy and covered a 365-day observation period. Three RDI categories and four anemia correction strategies were compared. Results. A total of 301 PFS events (50.6 %) were recorded. The proportions of patients without a recorded PFS event were 73.7 %, 51.5 %, and 19.5 % in the RDI ≥85 %, 85–65 %, and 65 % groups, respectively. These proportions were 57.8 % in patients with moderate anemia and 32.5 % in those with severe anemia; the OR for a PFS event in severe versus moderate anemia was 2.85 (95 % confidence interval (CI) 1.99–4.07). With epoetin alfa as the reference, the odds ratio for a PFS event were 6.99 (95 % CI 4.21–11.59) for no anemia correction, 5.44 (95 % CI 3.37–8.76) for iron preparations, and 7.75 (95 % CI 4.72–12.71) for blood transfusions. In the multivariable Cox model, the adjusted hazard ratio was 5.60 (95 % CI 3.99–7.86) for RDI 65 % versus ≥85 % and 5.71 (95 % CI 3.88–8.42) for no correction versus epoetin alfa. Conclusion. In this retrospective cohort, higher RDI and epoetin alfa use were associated with a greater proportion of patients without a recorded PFS event over 12 months of follow-up.
- 26 June 2026
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 48 (2) , 114-122
Clinical and economic aspects of prescribing granulocyte colony-stimulating factor
Objective. To evaluate economic significance of febrile neutropenia (FN) prophylaxis using granulocyte colony-stimulating factors (G-CSF) in oncology patients receiving antineoplastic drug therapy (ADT) within compulsory health insurance (CHI) system. Material and methods. We compared the total costs of CHI system when using two alternative G-CSF drugs (filgrastim 300 µg for 4 days and empegfilgrastim 7.5 mg once), direct costs of CHI system aimed at reimbursing hospitals for purchase of G-CSF and subsequent savings of CHI funds that could be spent on care for immediate and mid-term (up to 12 months) outcomes of prevented FN. Results. The estimated costs for prevention of FN determined by reimbursing purchase of a medicinal product and cost of care for FN and its consequences at the intermediate and final points of the study amounted to 43.81 billion rubles for filgrastim and 41.89 billion rubles for empegfilgrastim. The difference in such costs for empegfilgrastim (with complete abandonment of filgrastim) demonstrated savings for CHI budget in amount of 1.92 billion rubles/year or 16 071 rubles/year per a patient. Conclusion. Despite higher costs of empegfilgrastim, subsequent reduction of costs following more effective prevention of adverse outcomes will ensure a positive financial result for CHI system over a 12-month period.
- 26 June 2026
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 48 (2) , 114-122
Clinical and economic aspects of prescribing granulocyte colony-stimulating factor
Objective. To evaluate economic significance of febrile neutropenia (FN) prophylaxis using granulocyte colony-stimulating factors (G-CSF) in oncology patients receiving antineoplastic drug therapy (ADT) within compulsory health insurance (CHI) system. Material and methods. We compared the total costs of CHI system when using two alternative G-CSF drugs (filgrastim 300 µg for 4 days and empegfilgrastim 7.5 mg once), direct costs of CHI system aimed at reimbursing hospitals for purchase of G-CSF and subsequent savings of CHI funds that could be spent on care for immediate and mid-term (up to 12 months) outcomes of prevented FN. Results. The estimated costs for prevention of FN determined by reimbursing purchase of a medicinal product and cost of care for FN and its consequences at the intermediate and final points of the study amounted to 43.81 billion rubles for filgrastim and 41.89 billion rubles for empegfilgrastim. The difference in such costs for empegfilgrastim (with complete abandonment of filgrastim) demonstrated savings for CHI budget in amount of 1.92 billion rubles/year or 16 071 rubles/year per a patient. Conclusion. Despite higher costs of empegfilgrastim, subsequent reduction of costs following more effective prevention of adverse outcomes will ensure a positive financial result for CHI system over a 12-month period.
- Open Access
- 25 June 2026
- Published by Publishing House ABV Press in Oncohematology
- Vol. 21 (2) , 125-132
Models of organization and methods of payment for medical care for patients with malignant neoplasms and anemia at the expense of compulsory medical insurance
The availability of medication is directly determined by the ability to reimburse its costs, which determines the appropriateness of anemia therapy and the prognosis for cancer patients. Aim of the work was to assess the potential for financing medical care for patients with malignant neoplasms and anemia using compulsory medical insurance. A review of payment methods for medical care for patients with malignant neoplasms and anemia using compulsory medical insurance funds in accordance with Russian legislation was conducted. Models of medical care organization are identified depending on the suspected etiology of anemia. Suitable payment methods for each model are substantiated. For patients who develop anemia after starting anticancer therapy, there are several options for paying for medical care using compulsory medical insurance: 1) a single clinical statistical group with antitumor therapy [ds19.157–ds19.180; st19.182–st19.202], as well as a patient treatment complexity coefficient sl005 for a concomitant disease – unspecified anemia (International Classification of Diseases, 10th revision code D64.9) (i.e. without an established etiology); 2) 1st clinical statistical group (1st insurance event) with antitumor therapy [ds19.157–ds19.180; st19.182–st19.202]; 2nd clinical statistical group (2nd insurance event) with treatment for anemia of specified etiology (except International Classification of Diseases, 10th revision code D64.9) [ds05.001–ds05.002; st05.001–st05.002]. A decision-making algorithm has been developed to ensure a legal mechanism for the use of treatment complexity coefficient, within the framework of which erythropoiesis-stimulating drugs for unspecified anemia are prescribed before the diagnosis of anemia in malignant neoplasm is established. Compliance with the proposed decision-making algorithm before submitting an insurance claim for payment with treatment complexity coefficient s1005 for unspecified anemia opens up opportunities for insurance coverage of erythropoiesis-stimulating drugs in oncology medical organizations, which increases the availability of drug treatment for patients insured under compulsory medical insurance.
- 25 June 2026
- Published by Publishing House ABV Press in Oncohematology
- Vol. 21 (2) , 125-132
Open AccessModels of organization and methods of payment for medical care for patients with malignant neoplasms and anemia at the expense of compulsory medical insurance
The availability of medication is directly determined by the ability to reimburse its costs, which determines the appropriateness of anemia therapy and the prognosis for cancer patients. Aim of the work was to assess the potential for financing medical care for patients with malignant neoplasms and anemia using compulsory medical insurance. A review of payment methods for medical care for patients with malignant neoplasms and anemia using compulsory medical insurance funds in accordance with Russian legislation was conducted. Models of medical care organization are identified depending on the suspected etiology of anemia. Suitable payment methods for each model are substantiated. For patients who develop anemia after starting anticancer therapy, there are several options for paying for medical care using compulsory medical insurance: 1) a single clinical statistical group with antitumor therapy [ds19.157–ds19.180; st19.182–st19.202], as well as a patient treatment complexity coefficient sl005 for a concomitant disease – unspecified anemia (International Classification of Diseases, 10th revision code D64.9) (i.e. without an established etiology); 2) 1st clinical statistical group (1st insurance event) with antitumor therapy [ds19.157–ds19.180; st19.182–st19.202]; 2nd clinical statistical group (2nd insurance event) with treatment for anemia of specified etiology (except International Classification of Diseases, 10th revision code D64.9) [ds05.001–ds05.002; st05.001–st05.002]. A decision-making algorithm has been developed to ensure a legal mechanism for the use of treatment complexity coefficient, within the framework of which erythropoiesis-stimulating drugs for unspecified anemia are prescribed before the diagnosis of anemia in malignant neoplasm is established. Compliance with the proposed decision-making algorithm before submitting an insurance claim for payment with treatment complexity coefficient s1005 for unspecified anemia opens up opportunities for insurance coverage of erythropoiesis-stimulating drugs in oncology medical organizations, which increases the availability of drug treatment for patients insured under compulsory medical insurance.
- Open Access
- 3 February 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (4) , 65-74
Assessment of the need for financial provision of pharmacotherapy for anemia in patients with malignant neoplasms through funds from compulsory medical insurance
Aim: To evaluate the economic feasibility of reimbursing healthcare organizations for the costs of pharmacotherapy for anemia associated with malignant neoplasms during the period of antitumor pharmacotherapy and to propose mechanisms for its financial provision through funds from compulsory medical insurance. Materials and methods: А retrospective economic evaluation was conducted in 13 federal subjects of the Russian Federation, assessing various treatment options for anemia associated with malignant neoplasms in terms of financial expenditures for subsequent medical care delivery. This evaluation determined the effectiveness of anemia treatment based on prevented complications (predictable consequences of progression, including hypoxia, ischemia of organs and tissues, and reduced efficiency of pharmacotherapy), which require insurance coverage through funds from compulsory medical insurance. Results: The estimated costs for procuring erythropoiesis-stimulating agents range from 597.4 million rubles per year to 668.2 million rubles per year. Due to the savings achieved by eliminating the need for insurance coverage to compensate for the costs of treating anemia associated with malignant neoplasms following anticancer drug therapy (prevented insurance cases), a return on investment of 35.0 % is projected within the first 12 months, and 101.7 % within 36 months. Conclusions: The introduction of a separate payment method for medical care, which would enable reimbursement of costs for treating anemia associated with malignant neoplasms concurrently with antitumor pharmacotherapy for each administration of erythropoiesis-stimulating agents, is justified by a prognostic calculation indicating full cost recovery for the procurement of such agents over a 3-year observation period.
- 3 February 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (4) , 65-74
Open AccessAssessment of the need for financial provision of pharmacotherapy for anemia in patients with malignant neoplasms through funds from compulsory medical insurance
Aim: To evaluate the economic feasibility of reimbursing healthcare organizations for the costs of pharmacotherapy for anemia associated with malignant neoplasms during the period of antitumor pharmacotherapy and to propose mechanisms for its financial provision through funds from compulsory medical insurance. Materials and methods: А retrospective economic evaluation was conducted in 13 federal subjects of the Russian Federation, assessing various treatment options for anemia associated with malignant neoplasms in terms of financial expenditures for subsequent medical care delivery. This evaluation determined the effectiveness of anemia treatment based on prevented complications (predictable consequences of progression, including hypoxia, ischemia of organs and tissues, and reduced efficiency of pharmacotherapy), which require insurance coverage through funds from compulsory medical insurance. Results: The estimated costs for procuring erythropoiesis-stimulating agents range from 597.4 million rubles per year to 668.2 million rubles per year. Due to the savings achieved by eliminating the need for insurance coverage to compensate for the costs of treating anemia associated with malignant neoplasms following anticancer drug therapy (prevented insurance cases), a return on investment of 35.0 % is projected within the first 12 months, and 101.7 % within 36 months. Conclusions: The introduction of a separate payment method for medical care, which would enable reimbursement of costs for treating anemia associated with malignant neoplasms concurrently with antitumor pharmacotherapy for each administration of erythropoiesis-stimulating agents, is justified by a prognostic calculation indicating full cost recovery for the procurement of such agents over a 3-year observation period.
- Open Access
- 3 November 2025
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 15 (3) , 83-96
Predicting outcomes in patients with anemia and malignant neoplasms
Introduction. Anemia is a common complication of malignancies and anticancer treatment. In this regard, it is of great importance to predict the most likely outcomes in cancer patients with this pathology in the distant and medium periods.Aim. To analyze the factors that determine the prognosis in patients with anemia in malignant neoplasms and develop a methodological approach to predicting adverse, including fatal, outcomes in such patients in 3- and 5-year follow-up periods.Materials and methods. A cohort retrospective study was conducted. A group of patients with anemia in malignant neoplasms who received medical care was identified. To assess the factors that determine the outcome of this pathology, patients are divided according to the binary principle. The minimum sample size was determined using Altman nomograms. methods of non-parametric statistics (χ2-criterium) were used for statistical processing of data. The assessment of factors that cause an unfavorable prognosis in patients with anemia in malignant neoplasms was carried out by calculating the diagnostic coefficient according to A. wald and the informative coefficient according to S. kulbak.Results. It was found that the greatest role in formation of an unfavorable outcome of cancer is played by cardiovascular diseases, diabetes mellitus and cirrhosis of the liver. Among the therapeutic measures, the pathogenetic treatment of anemia with drugs that stimulate erythropoiesis, started during the period of antitumor therapy, has the greatest effect on the favorable outcome, which causes an increase in frequency of favorable outcomes to 5.5 and 4.8 % over 3 and 5 years, respectively.Conclusion. The methodological approach developed by us to assess probabilities of formation of adverse outcomes in patients with anemia in malignant neoplasms can be used to solve expert and clinical problems, determination the risk of an unfavorable outcome and justification the indications for the timely start of therapy.
- 3 November 2025
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 15 (3) , 83-96
Open AccessPredicting outcomes in patients with anemia and malignant neoplasms
Introduction. Anemia is a common complication of malignancies and anticancer treatment. In this regard, it is of great importance to predict the most likely outcomes in cancer patients with this pathology in the distant and medium periods.Aim. To analyze the factors that determine the prognosis in patients with anemia in malignant neoplasms and develop a methodological approach to predicting adverse, including fatal, outcomes in such patients in 3- and 5-year follow-up periods.Materials and methods. A cohort retrospective study was conducted. A group of patients with anemia in malignant neoplasms who received medical care was identified. To assess the factors that determine the outcome of this pathology, patients are divided according to the binary principle. The minimum sample size was determined using Altman nomograms. methods of non-parametric statistics (χ2-criterium) were used for statistical processing of data. The assessment of factors that cause an unfavorable prognosis in patients with anemia in malignant neoplasms was carried out by calculating the diagnostic coefficient according to A. wald and the informative coefficient according to S. kulbak.Results. It was found that the greatest role in formation of an unfavorable outcome of cancer is played by cardiovascular diseases, diabetes mellitus and cirrhosis of the liver. Among the therapeutic measures, the pathogenetic treatment of anemia with drugs that stimulate erythropoiesis, started during the period of antitumor therapy, has the greatest effect on the favorable outcome, which causes an increase in frequency of favorable outcomes to 5.5 and 4.8 % over 3 and 5 years, respectively.Conclusion. The methodological approach developed by us to assess probabilities of formation of adverse outcomes in patients with anemia in malignant neoplasms can be used to solve expert and clinical problems, determination the risk of an unfavorable outcome and justification the indications for the timely start of therapy.
- Open Access
- 1 January 2025
- Published by Geotar-Media Publishing Group in Healthcare Management: News. Views. Education. Bulletin of VSHOUZ
- Vol. 11 (1)
The methodology of expert assessment of quality of medical care for patients with peptic ulcer disease
Методика экспертной оценки качества оказания медицинской помощи пациентам с язвенной болезнью
- 1 January 2025
- Published by Geotar-Media Publishing Group in Healthcare Management: News. Views. Education. Bulletin of VSHOUZ
- Vol. 11 (1)
Open AccessThe methodology of expert assessment of quality of medical care for patients with peptic ulcer disease
Методика экспертной оценки качества оказания медицинской помощи пациентам с язвенной болезнью